Table 1 Characteristics of confirmed vs. unconfirmed ILD cases following clinical adjudication
Yes, confirmed ILD | No, not confirmed ILD | Insufficient information to determine | P value | SMD (comparing all three groups) | |
|---|---|---|---|---|---|
N | 108 | 126 | 39 | ||
Age (mean (sd)) | 66 (9.7) | 67 (9.6) | 67 (10.2) | 0.80 | 0.06 |
Male sex (%) | 36 (33.3) | 32 (25.4) | 7 (17.9) | 0.14 | 0.24 |
Race (%) | 0.52 | 0.34 | |||
White | 78 (72.9) | 92 (73.6) | 32 (82.1) | - | - |
Black | 22 (20.6) | 21 (16.8) | 7 (17.9) | - | - |
Unknown | 5 (4.7) | 10 (8.0) | 0 (0.0) | - | - |
Other | 2 (1.9) | 2 (1.6) | 0 (0.0) | - | - |
Weighted Charlson indexa (mean (sd)) | 2 (1.5) | 2 (1.5) | 2 (1.9) | 0.95 | 0.03 |
Comorbidities | |||||
Cerebrovascular disease (%) | 8 (7.4) | 11 (8.7) | 2 (5.1) | 0.75 | 0.10 |
Congestive heart failure (%) | 15 (13.9) | 21 (16.7) | 7 (17.9) | 0.78 | 0.07 |
Diabetes without complications (%) | 26 (24.1) | 18 (14.3) | 11 (28.2) | 0.07 | 0.23 |
Diabetes with complications (%) | 8 (7.4) | 6 (4.8) | 2 (5.1) | 0.68 | 0.07 |
Myocardial infarction (%) | 9 (8.3) | 6 (4.8) | 2 (5.1) | 0.51 | 0.10 |
Peripheral vascular disease (%) | 11 (10.2) | 14 (11.1) | 3 (7.7) | 0.83 | 0.08 |
Renal disease (%) | 9 (8.3) | 14 (11.1) | 5 (12.8) | 0.67 | 0.10 |
Any tobacco use (%) | 21 (19.4) | 30 (23.8) | 11 (28.2) | 0.49 | 0.14 |
RA Medications, any prior use (%) | |||||
Methotrexate (%) | 39 (36.1) | 56 (44.4) | 20 (51.3) | 0.20 | 0.21 |
Biologic DMARDS (%) | 43 (39.8) | 49 (38.9) | 10 (25.6) | 0.26 | 0.20 |
Glucocorticoids, e.g., prednisone (%) | 69 (63.9) | 70 (55.6) | 23 (59.0) | 0.43 | 0.11 |